SSTI, intraabdominal infection, gynecologic infection1.5-3 g IV q6h (max 12 g/d)

SSTI, intraabdominal infectionSafety and efficacy in pediatric patients <1y of age have not been established300 mg/kg IV #4 (max 12 g/d)If BW >40 kg, refer to adult dose

CrCl ≥30CrCl 15-29CrCl 5-14HDCRRTNo dose adjustmentRecommended dose IV q12hRecommended dose IV q24h3 g q24h (give after hemodialysis on dialysis day)3 g q12h

General Information

A broad spectrum of activity allows use for many types of infections (e.g. appendicitis, diverticulitis, peritonitis).

Infection of skin and/or subcutaneous tissue.

Infectious disease of abdomen.

Pelvic inflammatory disease.

Obtain WBC count to indicate whether the infection is clearing.

Perform culture and susceptibility tests before initiating therapy.

Monitor hepatic function in patients with hepatic impairment at regular intervals.


  • Rash

  • Diarrhea

  • Injection site pain


  • Clostridium difficile colitis

  • Clostridium difficile diarrhea

  • Hepatotoxicity

Major drug-drug interactions

  • Amifampridine

  • Atenolol

  • Burpropion

  • Chlortetracycline

  • Cholera vaccine, live

  • Demeclocycline

  • Donepezil

  • Doxycycline

  • Eravacycline

  • Lymecycline

  • Melocycline

  • Methacycline

  • Minocycline

  • Omadacycline

  • Oxytetracycline

  • Rolitetracycline

  • Sarecycline

  • Tetracycline

  • Tigecycline

  • Warfarin

Antimicrobial class: Antibiotic, Beta-Lactamase Inhibitor, Aminopenicillin

Pregnancy category: B

Average serum half life: 1 hour

Lung penetration: Therapeutic

CSF penetration: Therapeutic

Biliary penetration: Therapeutic


  • Dose adjustment necessary in renal impairment.

  • Monitoring recommended in patients with hepatic impairment.

  • Discontinuation may be necessary in Clostridium difficile-associated diarrhea.

  • Discontinuation warranted in severe skin reactions and allergic reactions.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.